Hansa Biopharma to host Q2 2024 interim results conference call
Comunicato Precedente
Comunicato Successivo
To participate in the telephone conference, please use the dial-in details provided below:
Sweden: +46-8-1241-0952
United Kingdom: +44-203-7696819
United States: +1 646-787-0157
Participant access code: 765135
The webcast will be available on https://hansabiopharma.eventcdn.net/events/half-year-january-june-2024
Contacts for more information:
Evan Ballantyne, Chief Financial Officer
[email protected]
Stephanie Kenney, VP Global Corporate Affairs
[email protected]
Notes to editors
About Hansa Biopharma
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.
©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/hansa-biopharma-to-host-q2-2024-interim-results-conference-call-302188679.html
